EP4649946A1 — Compositions for treating arterial hypertension
Assigned to Alba Research Srl · Expires 2025-11-19 · 0y expired
What this patent protects
The present invention concerns a composition for the treatment of hypertensive patients, with chronic ischemic heart disease and heart failure. The invention provides a pharmaceutical composition comprising or consisting of an aliquot of: (a) at least one compound of the pharmac…
USPTO Abstract
The present invention concerns a composition for the treatment of hypertensive patients, with chronic ischemic heart disease and heart failure. The invention provides a pharmaceutical composition comprising or consisting of an aliquot of: (a) at least one compound of the pharmacological class of β-blockers, such as bisoprolol and/or nebivolol; (b) a selective angiotensin II receptor (AT 1 ) inhibitor belonging to the pharmacological class of sartans, such as candesartan. Components (a) and (b) can be associated with a third component (c) belonging to the pharmacological class of diuretics, such as indapamide. Components (a), (b) and optionally (c) are supplied in a single formulation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.